Group 1 - Sterling Infrastructure (STRL) has an average brokerage recommendation (ABR) of 1.00, indicating a Strong Buy based on recommendations from four brokerage firms, all of which are Strong Buy [2][4] - The Zacks Consensus Estimate for Sterling Infrastructure's earnings has increased by 2.7% over the past month to $9.57, reflecting analysts' growing optimism about the company's earnings prospects [13] - The recent change in the consensus estimate, along with other factors, has resulted in a Zacks Rank 1 (Strong Buy) for Sterling Infrastructure, suggesting a potential for stock price appreciation [14] Group 2 - Brokerage recommendations often exhibit a strong positive bias due to the vested interests of brokerage firms, leading to a higher number of Strong Buy ratings compared to Strong Sell ratings [6][10] - The Zacks Rank is a quantitative model based on earnings estimate revisions, which has shown a strong correlation with near-term stock price movements, making it a more reliable indicator than ABR [11][12] - The ABR may not always be up-to-date, while the Zacks Rank reflects timely changes in earnings estimates, providing a more accurate prediction of future stock prices [12]

苹果公司周四被两家机构下调评级，成为市场对这家iPhone制造商持谨慎态度的最新迹象。今年以来， 苹果表现大幅落后于其他大型科技股。随着评级下调，苹果的"推荐一致性"（即买入、持有和卖出评级 的比例指标）已降至3.9（满分为5分），创2020年初以来最低水平。在彭博追踪的分析师中，仅有55% 的人推荐买入该股，在大型科技股中属极低水平。相比之下，英伟达、微软和亚马逊均超过90%。 来源：滚动播报 ...

Summary of Analyst Ratings Changes Core Viewpoint - Top Wall Street analysts have revised their outlook on several companies, providing new ratings and price targets for their stocks [1]. Company-Specific Summaries - **Eaton Corporation plc (ETN)**: Daiwa Capital analyst Jairam Nathan initiated coverage with an Outperform rating and a price target of $390, while shares closed at $362.25 [6]. - **Synaptics Incorporated (SYNA)**: Deutsche Bank analyst Ross Seymore initiated coverage with a Buy rating and a price target of $85, with shares closing at $69.10 [6]. - **Celsius Holdings, Inc. (CELH)**: Goldman Sachs analyst Bonnie Herzog initiated coverage with a Buy rating and a price target of $72, while shares closed at $56.22 [6]. - **Solventum Corporation (SOLV)**: Jefferies analyst Michael Toomey initiated coverage with a Hold rating and a price target of $80, with shares closing at $71.22 [6]. - **10x Genomics, Inc. (TXG)**: Piper Sandler analyst David Westenberg initiated coverage with a Neutral rating and a price target of $15, while shares closed at $12.59 [6].

Core Viewpoint - The article discusses the reliability of brokerage recommendations, particularly focusing on DraftKings (DKNG), and emphasizes the importance of using these recommendations in conjunction with other analytical tools for making investment decisions [1][5][10]. Group 1: Brokerage Recommendations for DraftKings - DraftKings has an average brokerage recommendation (ABR) of 1.27, indicating a consensus between Strong Buy and Buy, based on recommendations from 31 brokerage firms [2]. - Out of the 31 recommendations, 25 are classified as Strong Buy and 3 as Buy, which represent 80.7% and 9.7% of all recommendations respectively [2]. Group 2: Limitations of Brokerage Recommendations - Studies indicate that brokerage recommendations have limited success in guiding investors towards stocks with the highest price increase potential [5]. - Analysts from brokerage firms tend to exhibit a strong positive bias in their ratings, often issuing five "Strong Buy" recommendations for every "Strong Sell" [6][10]. - The interests of brokerage firms may not align with those of retail investors, leading to potential misguidance regarding stock price movements [7][10]. Group 3: Zacks Rank as an Alternative Tool - The Zacks Rank is presented as a more reliable indicator of a stock's near-term price performance, based on earnings estimate revisions rather than brokerage recommendations [8][11]. - The Zacks Rank is distinct from ABR, as it is a quantitative model that reflects earnings estimate revisions and is displayed in whole numbers [9]. - The Zacks Rank is updated more frequently than ABR, making it a timely tool for predicting future stock prices [12]. Group 4: Current Earnings Estimates for DraftKings - The Zacks Consensus Estimate for DraftKings remains unchanged at $1.33 for the current year, suggesting steady analyst views on the company's earnings prospects [13]. - Due to the unchanged consensus estimate and other factors, DraftKings holds a Zacks Rank of 3 (Hold), indicating a cautious approach despite the Buy-equivalent ABR [14].

Core Viewpoint - Investors have become less optimistic about Diamondback Energy's future following a price target reduction by an analyst, resulting in a more than 5% loss in stock value on that trading day [1] Group 1: Analyst Actions - Tim Rezvan from KeyCorp's KeyBanc Capital Markets lowered his price target for Diamondback Energy to $176 per share from $180, while maintaining an overweight (buy) rating on the stock [2] - The price target adjustment was influenced by Diamondback's revision of natural gas price estimates and the acquisition of Sitio Royalties by its subsidiary Viper Energy [4] Group 2: Acquisition Details - Viper Energy completed an all-cash acquisition of Sitio Royalties valued at $4.1 billion, which closed in mid-August [5] - Following the acquisition, Viper raised its base dividend by 10% and revised its third-quarter production guidance to an average of 104,000 to 110,000 barrels of oil equivalent per day [4][5] Group 3: Financial Performance - Diamondback Energy reported a nearly 50% year-over-year increase in revenue, reaching $3.68 billion in the second quarter [6] - Despite a decline in adjusted net income, the company still posted a profit of $785 million [6]

Core Insights - Vertex Pharmaceuticals reported strong Q2 2025 earnings, with adjusted earnings of $4.52 per share, exceeding the Zacks Consensus Estimate of $4.24, and a significant recovery from an adjusted loss of $12.83 per share in the same quarter last year [2][14] - Total revenues reached $2.96 billion, surpassing the Zacks Consensus Estimate of $2.89 billion, marking a 12% year-over-year increase driven by higher sales of Trikafta/Kaftrio and contributions from new drugs [3][4] Financial Performance - U.S. revenues rose 14% year over year to $1.85 billion, while international sales increased 8% to $1.12 billion, reflecting strong demand and growth in cystic fibrosis (CF) treatments [4] - Trikafta sales were $2.55 billion, a 4.2% increase year over year, slightly missing the Zacks Consensus Estimate of $2.56 billion [5] - New drug Alyftrek generated $156.8 million in sales, showing a significant increase from $53.9 million in Q1 2025, with steady uptake among eligible patient groups [6][7] Product Developments - Casgevy sales surged 114.1% sequentially to $30.4 million, indicating strong adoption and progress in patient treatment [8][9] - Journavx generated $12 million in sales, with over 110,000 prescriptions written since its launch, and positive feedback from physicians and patients [10][11] Cost Management - Adjusted R&D expenses increased 25.9% year over year to $878.1 million, while SG&A expenses rose 28.2% to $359.4 million, reflecting investments in pipeline development and product launches [13] - Adjusted operating income was approximately $1.33 billion, a significant recovery from an adjusted operating loss of $3.15 billion in the previous year [14] Future Guidance - Vertex maintains its total revenue guidance for 2025 in the range of $11.85-$12 billion, indicating an 8% growth at the midpoint, driven by CF franchise growth and new product contributions [15] - Combined adjusted R&D, AIPR&D, and SG&A expense guidance for 2025 is projected between $4.9-$5 billion, with an expected adjusted tax rate of 20.5%-21.5% [16] Shareholder Actions - Vertex announced a new $4 billion share repurchase program, building on an existing $3 billion program, indicating a commitment to returning value to shareholders [17]

Core Viewpoint - Encompass Health has shown strong performance in its recent earnings report, with significant growth in earnings and revenues, leading to an optimistic outlook for the company moving forward [3][10][11]. Financial Performance - Encompass Health reported Q2 2025 adjusted EPS of $1.40, exceeding estimates by 16.7% and reflecting a 26.1% year-over-year increase [3][4]. - Net operating revenues for Q2 2025 rose 12% year-over-year to $1.5 billion, surpassing consensus estimates by 2.3% [3][4]. - Net income increased by 26.2% year-over-year to $184.9 million, while adjusted EBITDA improved 17.4% year-over-year to $318.6 million, exceeding estimates [6][8]. Operational Highlights - The company added 26 beds to existing hospitals and opened a new de novo hospital during the quarter [4][6]. - Net patient revenue per discharge grew 4.2% year-over-year to $21.7 billion, with total discharges improving by 7.2% year-over-year to 65,237 [5][6]. Financial Position - As of June 30, 2025, Encompass Health had cash and cash equivalents of $99.1 million, up from $85.4 million at the end of 2024 [7]. - Total assets increased by 3.8% to $6.8 billion, while long-term debt decreased by 1.6% to $2.3 billion [7][8]. Capital Deployment - The company repurchased shares worth $24.7 million in Q2 2025 and has approximately $433 million remaining under its buyback authorization [9]. - A quarterly cash dividend of 17 cents per share was paid, which was increased to 19 cents per share in July [9]. Future Outlook - Encompass Health raised its 2025 revenue forecast to between $5.88 billion and $5.98 billion, indicating a 10.4% increase from 2024 [10]. - Adjusted EPS for 2025 is now expected to be between $5.12 and $5.34, suggesting an 18.1% growth from the previous year [11]. - The company aims to open seven de novo hospitals and add 340 beds in 2025, with a long-term growth target of 6-8% CAGR in discharges from 2023 to 2027 [12][13]. Market Position - Encompass Health is positioned favorably within the Zacks Medical - Outpatient and Home Healthcare industry, with a Zacks Rank 2 (Buy) indicating expected above-average returns in the coming months [16][17].

Core Viewpoint - The article discusses the reliability of brokerage recommendations, particularly focusing on Marathon Digital Holdings, Inc. (MARA), and highlights the potential misalignment of interests between brokerage analysts and retail investors [1][10]. Brokerage Recommendations - Marathon Digital has an average brokerage recommendation (ABR) of 2.00, indicating a "Buy" based on recommendations from 14 brokerage firms, with seven (50%) classified as "Strong Buy" [2]. - Despite the positive ABR, the article cautions against making investment decisions solely based on this metric, as studies show limited success of brokerage recommendations in predicting stock price increases [5][10]. Zacks Rank Comparison - The Zacks Rank, a proprietary stock rating tool, categorizes stocks from 1 (Strong Buy) to 5 (Strong Sell) and is based on earnings estimate revisions, which have a strong correlation with near-term stock price movements [8][11]. - The Zacks Rank for Marathon Digital is 3 (Hold), indicating a cautious outlook, as the consensus estimate for the current year remains unchanged at -$0.17 [13][14]. Analyst Behavior - Analysts from brokerage firms tend to exhibit a strong positive bias in their recommendations, often issuing five "Strong Buy" ratings for every "Strong Sell," which can mislead investors [6][10]. - The ABR may not be up-to-date, while the Zacks Rank reflects timely earnings estimate revisions, making it a more reliable indicator for future price movements [12].

Core Viewpoint - C.H. Robinson Worldwide, Inc. reported mixed second-quarter 2025 results, with earnings exceeding estimates while revenues fell short [2][3]. Financial Performance - Quarterly earnings per share were $1.29, surpassing the Zacks Consensus Estimate of $1.17, and improved by 12.2% year over year [3]. - Total revenues amounted to $4.13 billion, missing the Zacks Consensus Estimate of $4.22 billion, and decreased by 7.7% year over year due to the divestiture of the Europe Surface Transportation business, lower pricing in ocean services, and reduced fuel surcharges in truckload services [3]. - Adjusted gross profits grew by 0.8% year over year to $693.2 million, driven by higher adjusted gross profit per transaction in customs, truckload, and less than truckload (LTL) services, partially offset by the divestiture and lower ocean service volumes [4]. Segment Performance - North American Surface Transportation revenues were $2.91 billion, down 2.4% year over year, attributed to lower fuel surcharges in truckload services, with adjusted gross profits growing 3% to $432.24 million [5]. - Global Forwarding revenues fell 13.4% year over year to $797.80 million due to lower pricing in ocean services, while adjusted gross profits increased by 1.9% to $187.58 million [6]. - Revenues from other sources decreased by 26.5% year over year to $420.51 million, with adjusted gross profits from transportation services totaling $693.23 million, up 0.8% from the prior year [7][8]. Balance Sheet and Cash Flow - At the end of Q2, cash and cash equivalents were $155.99 million, up from $129.94 million in the previous quarter, while long-term debt slightly increased to $922.31 million [9]. - Cash generated from operations was $227.1 million, up from $166.4 million in the year-ago quarter, driven by a $60.7 million increase in cash flow [10]. - The company returned $160.7 million to shareholders, including $74.9 million in cash dividends and $85.8 million through share repurchases [10]. Market Outlook - Estimates for C.H. Robinson have trended upward over the past month, indicating a positive outlook [11][13]. - The company holds a Zacks Rank 3 (Hold), suggesting an expectation of in-line returns in the coming months [13].

Core Insights - BJ's Wholesale Club reported second-quarter adjusted earnings per share of $1.14, exceeding the analyst consensus estimate of $1.09, while quarterly sales of $5.38 billion (+3.4% year over year) fell short of the expected $5.48 billion [1] - The company raised its fiscal year 2025 adjusted EPS guidance to $4.20–$4.35 from the previous range of $4.10–$4.30, which is slightly below the Street estimate of $4.31 [2] - Comparable club sales for fiscal year 2025, excluding gasoline sales, are projected to increase by 2.0% to 3.5% year-over-year [3] Analyst Ratings and Price Targets - UBS analyst Mark Carden maintained a Buy rating on BJ's Wholesale and lowered the price target from $135 to $125 [5] - DA Davidson analyst Michael Baker also maintained a Buy rating, reducing the price target from $140 to $123 [5] - Morgan Stanley analyst Simeon Gutman kept an Equal-Weight rating and cut the price target from $125 to $115 [5] - JP Morgan analyst Christopher Horvers maintained a Neutral rating and lowered the price target from $113 to $110 [5] - Citigroup analyst Paul Lejuez maintained a Buy rating and reduced the price target from $120 to $115 [5] - Evercore ISI Group analyst Greg Melich maintained an In-Line rating and lowered the price target from $117 to $110 [5]